NASDAQ:IRWD - Ironwood Pharmaceuticals Stock Price, Forecast & News

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) released its quarterly earnings data on Thursday, February, 13th. The biotechnology company reported $0.30 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.22 by $0.08. The biotechnology company had revenue of $126.30 million for the quarter, compared to analyst estimates of $112.06 million. Ironwood Pharmaceuticals had a negative return on equity of 46.52% and a net margin of 5.02%. The business's quarterly revenue was down 3.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.02) EPS. View Ironwood Pharmaceuticals' Earnings History.

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals issued an update on its FY 2020 Pre-Market earnings guidance on Thursday, February, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $360-380 million, compared to the consensus revenue estimate of $391.25 million.

8 analysts have issued 1-year price targets for Ironwood Pharmaceuticals' shares. Their forecasts range from $12.00 to $20.00. On average, they expect Ironwood Pharmaceuticals' share price to reach $14.29 in the next year. This suggests a possible upside of 22.8% from the stock's current price. View Analyst Price Targets for Ironwood Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ironwood Pharmaceuticals.

Media stories about IRWD stock have been trending very negative recently, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ironwood Pharmaceuticals earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near future. View News Stories for Ironwood Pharmaceuticals.

Some companies that are related to Ironwood Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Micron Technology (MU), Allergan (AGN), Aegean Marine Petroleum Network (ANW) and Continental Resources (CLR).

Ironwood Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include UBS Asset Management Americas Inc. (5.58%), Janus Henderson Group PLC (5.29%), State Street Corp (3.68%), EcoR1 Capital LLC (2.79%), Credit Suisse AG (1.95%) and Geode Capital Management LLC (1.40%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Kelly Macdonald, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

IRWD stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., Bank of America Corp DE, EcoR1 Capital LLC, Credit Suisse AG, Broderick Brian C, UBS Group AG, Rafferty Asset Management LLC and State Street Corp. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Kelly Macdonald, Lawrence S Olanoff, Mark G Currie and Thomas A Mccourt. View Insider Buying and Selling for Ironwood Pharmaceuticals.

IRWD stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Renaissance Technologies LLC, Pictet Asset Management Ltd., Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., Hodges Capital Management Inc., Panagora Asset Management Inc. and Russell Investments Group Ltd.. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IRWD stock can currently be purchased for approximately $11.63.

Ironwood Pharmaceuticals has a market capitalization of $1.82 billion and generates $428.41 million in revenue each year. The biotechnology company earns $21.50 million in net income (profit) each year or $0.55 on an earnings per share basis. Ironwood Pharmaceuticals employs 515 workers across the globe.View Additional Information About Ironwood Pharmaceuticals.

The official website for Ironwood Pharmaceuticals is http://www.ironwoodpharma.com/.

Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]